Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CAPSULE
**DOSAGE REGIMEN AND ADMINISTRATION** **Dosage regimen** **General target population** The recommended dosage of Seebri Breezhaler is the once-daily inhalation of the content of one 50 microgram capsule using the Seebri Breezhaler inhaler. **Special Population** **Renal impairment** Seebri Breezhaler can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis, Seebri Breezhaler should be used only if the expected benefit outweighs the potential risk. See sections WARNINGS AND PRECAUTIONS and CLINICAL PHARMACOLOGY – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. **Hepatic impairment** No specific studies have been conducted in patients with hepatic impairment. Seebri Breezhaler is predominantly cleared by renal excretion and therefore no major increase in exposure is expected in patients with hepatic impairment. No dose adjustment is required in patients with hepatic impairment. **Pediatric patients (below 18 years)** Seebri Breezhaler should not be used in patients under 18 years of age. **Geriatric patients (75 years of age or above)** Seebri Breezhaler can be used at the recommended dose in elderly patients 75 years of age and older. **Method of administration** Seebri Breezhaler capsules must be administered only by the oral inhalation route and only using the Seebri Breezhaler inhaler. Seebri Breezhaler capsules must not be swallowed (see section OVERDOSAGE – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Seebri Breezhaler is recommended to be administered once-daily at the same time of the day each day. If a dose is missed, the next dose should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day. Seebri Breezhaler capsules must always be stored in the blister to protect from moisture, and only removed IMMEDIATELY BEFORE USE. When prescribing Seebri Breezhaler patients should be instructed on correct use of the inhaler. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicine rather than inhaling it.
BUCCAL
Medical Information
**INDICATIONS** Seebri Breezhaler is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
**CONTRAINDICATIONS** Seebri Breezhaler is contraindicated in patients with hypersensitivity to glycopyrronium or to any of the excipients of the preparations (see sections DESCRIPTION AND COMPOSITION and WARNINGS AND PRECAUTIONS – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
R03BB06
glycopyrronium bromide
Manufacturer Information
NOVARTIS (SINGAPORE) PTE LTD
Novartis Pharma Schweizerhalle AG (Post micronisation treatment of Intermediate)
Novartis Pharma Stein AG (manufacturer and secondary packager)
Siegfried Barbera, S.L